Table 1

 Summary of studies included in meta-analysis of trials of the efficacy of fluticasone propionate in children with asthma

StudyNo. of patientsDuration of study (weeks)Dose of fluticasone (µg/day)DeviceRange (mean) of FEV1 as % of predictedAge (mean)Baseline ICS usage*Outcome measures
FEV1Morning PEFEvening PEFβ-agonist useExacerbationsNight awakeningsSymptom score
FEV1, forced expiratory volume in one second; PEF, peak expiratory flow; MDI, metered dose inhaler.
*BDP or equivalent μg/day.
Placebo controlled
1543712Placebo 100 200Diskus Diskhaler50–85 (73)6–11⩾0
1726312Placebo 100 200MDIPEF 75–904–11 (8)None for 3/12
1415812Placebo 200Diskus50–85 (70)6–11 (8.5)⩾0
182584Placebo 100MDI(80)6–14 (9)None for 6/12X
163412Placebo 200Diskhaler>75 (90)8–14 (10.5)None for 1/12X
Non-placebo controlled
215552200 1000 step down to 100Diskhaler(91)6–10<800XX
2052852200 400DiskusPEF 1034–11 (8)800–1600 or ⩽5 mg/day prednisoneXX